Partner Fund Management L.P. decreased its position in shares of Kura Oncology Inc (NASDAQ:KURA) by 18.8% during the 2nd quarter, HoldingsChannel reports. The fund owned 1,087,123 shares of the company’s stock after selling 252,239 shares during the period. Partner Fund Management L.P.’s holdings in Kura Oncology were worth $19,786,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in the company. Sio Capital Management LLC boosted its stake in shares of Kura Oncology by 27.4% during the 2nd quarter. Sio Capital Management LLC now owns 837,604 shares of the company’s stock worth $15,244,000 after acquiring an additional 180,193 shares in the last quarter. Point72 Asset Management L.P. purchased a new stake in shares of Kura Oncology during the 2nd quarter worth approximately $2,412,000. Bank of America Corp DE boosted its stake in shares of Kura Oncology by 327.1% during the 2nd quarter. Bank of America Corp DE now owns 17,729 shares of the company’s stock worth $323,000 after acquiring an additional 13,578 shares in the last quarter. Prosight Management LP purchased a new stake in shares of Kura Oncology during the 2nd quarter worth approximately $5,240,000. Finally, Voya Investment Management LLC purchased a new stake in shares of Kura Oncology during the 2nd quarter worth approximately $187,000. 77.42% of the stock is currently owned by institutional investors and hedge funds.

Shares of Kura Oncology stock opened at $17.35 on Friday. The company has a debt-to-equity ratio of 0.04, a current ratio of 10.22 and a quick ratio of 10.22. Kura Oncology Inc has a 1 year low of $11.40 and a 1 year high of $24.02. The company has a market cap of $660.77 million, a P/E ratio of -11.41 and a beta of 4.14.

Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings data on Thursday, August 9th. The company reported ($0.45) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.45). analysts forecast that Kura Oncology Inc will post -1.73 EPS for the current fiscal year.

Several equities research analysts have recently commented on the company. HC Wainwright assumed coverage on Kura Oncology in a research note on Wednesday, August 1st. They set a “buy” rating and a $31.00 price target on the stock. BidaskClub raised Kura Oncology from a “sell” rating to a “hold” rating in a research note on Wednesday, July 4th. ValuEngine raised Kura Oncology from a “buy” rating to a “strong-buy” rating in a research note on Monday, July 2nd. Finally, Oppenheimer lifted their price objective on Kura Oncology from $27.00 to $35.00 and gave the stock an “outperform” rating in a research report on Monday, July 9th. Two investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $27.00.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancers. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.

Further Reading: Google Finance Portfolio Workaround

Want to see what other hedge funds are holding KURA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kura Oncology Inc (NASDAQ:KURA).

Institutional Ownership by Quarter for Kura Oncology (NASDAQ:KURA)

Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.